Scott E Turner

US Patent:

20050255509, Nov 17, 2005

Filed:

Mar 30, 2005

Appl. No.:

11/095029

Inventors:

Marc Hellerstein - Kensington CA, US
Scott Turner - Oakland CA, US

Assignee:

KineMed, Inc. - Emeryville CA

International Classification:

C12Q001/68

US Classification:

435006000

Abstract:

The methods of the present invention allow for the measurement of ribonucleotide reductase (RR) activity, an important enzyme in the de novo DNA synthesis pathway. Ribonucleotide reductase converts all four ribonucleotides to their deoxy form and is a rate-controlling step in this pathway. Biosynthetic pathways of deoxyribonucleotides (dN) have received considerable attention in the context of anti-proliferative chemotherapy. Inhibitors of various steps in dN biosynthesis, including inhibitors of RR are among the most useful chemotherapeutic agents in cancer, viral infections, and other therapeutic uses. DNA synthesis from the dN salvage pathway is also an important component to DNA replication. The relative contributions from RR vs. salvage pathways are critical to the actions and effectiveness of chemotherapeutic agents that act on nucleoside metabolic pathways. Until now, however, it has not been possible to study these metabolic processes in vivo. Disclosed within are methods of measuring RR activity in vivo and in vitro which find use, among other things, in drug discovery, development, and approval.

US Patent:

20110288114, Nov 24, 2011

Filed:

Jun 22, 2009

Appl. No.:

13/001281

Inventors:

Scott Turner - Oakland CA, US
Mary Wolff - Montana CA, US

Assignee:

Kinemed, Inc. - Emeryville CA

International Classification:

A61K 31/4355
A61P 25/00
A61P 29/00

US Classification:

514291

Abstract:

A method of treating a fibrotic disease or condition in a patient comprising administering noscapine and a pharmaceutical carrier to said patient.

US Patent:

20210147526, May 20, 2021

Filed:

Nov 13, 2020

Appl. No.:

17/098199

Inventors:

- South San Francisco CA, US
Chun Chen - Albany CA, US
Scott Turner - Oakland CA, US

International Classification:

C07K 16/18
A61K 45/06
A61P 25/28

Abstract:

Disclosed herein are pharmaceutical agents and compositions that activate integrin heterodimers that contain beta-1 integrin protein that specifically bind laminin protein. Such agents and compositions are useful for treating diseases related to muscle malfunction, including muscular dystrophies.

US Patent:

20190219585, Jul 18, 2019

Filed:

Jan 17, 2019

Appl. No.:

16/250721

Inventors:

- Rahway NJ, US
Jennifer H. Yearley - Palo Alto CA, US
Scott P. Turner - San Francisco CA, US
Belma Dogdas - Secaucus NJ, US
Ansuman Bagchi - Plainsboro NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

G01N 33/574
G16H 20/17
G16H 20/40
G06T 7/00
C07K 16/28
C12Q 1/6886
G06T 7/11
G06T 7/41
G06T 7/90
G16B 40/20

Abstract:

The present disclosure describes an IHC assay for detecting and quantifying spatially proximal pairs of PD-1-expressing cells (PD-1+ cells) and PD-Ligand-expressing cells (PD-L+ cells) in tumor tissue, and the use of the assay to generate proximity biomarkers that are predictive of which cancer patients are most likely to benefit from treatment with a PD-1 antagonist. The disclosure also provides methods for testing tumor samples for the proximity biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.

US Patent:

20160305947, Oct 20, 2016

Filed:

Dec 8, 2014

Appl. No.:

15/103050

Inventors:

- Rahway NJ, US
Jennifer H. Yearley - Palo Alto CA, US
Scott P. Turner - Sunnyvale CA, US
Belma Dogdas - Secaucus NJ, US
Ansuman Bagchi - Plainsboro NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

G01N 33/574
G06T 7/40
G06T 7/00
C07K 16/28

Abstract:

The present disclosure describes an IHC assay for detecting and quantifying spatially proximal pairs of PD-1-expressing cells (PD-1+ cells) and PD-Ligand-expressing cells (PD-L+ cells) in tumor tissue, and the use of the assay to generate proximity biomarkers that are predictive of which cancer patients are most likely to benefit from treatment with a PD-1 antagonist. The disclosure also provides methods for testing tumor samples for the proximity biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.